Table 3 Efficacy data derived from the PAC-SYM questionnaire
PlaceboPRU 2 mgPRU 4 mg
Secondary efficacy endpoints
Overall PAC-SYM symptoms score,† mean (mean change from baseline)
    Baseline2.062.122.00
    Week 121.69 (−0.37)1.44 (−0.66)***1.29 (−0.71)***
PAC-SYM stool symptoms score,† mean (mean change from baseline)
    Baseline2.472.562.45
    Week 122.08 (−0.40)1.75 (−0.78)***1.69 (−0.77)***
PAC-SYM abdominal symptoms score,† mean (mean change from baseline)
    Baseline2.122.202.04
    Week 121.72 (−0.40)1.53 (−0.66)*1.26 (−0.77)***
PAC-SYM rectal symptoms score,† mean (mean change from baseline)
    Baseline1.291.271.20
    Week 121.01 (−0.26)0.82 (−0.44)*0.67 (−0.54)***
  • †Decreases reflect improvement. Asterisks indicate significant differences versus placebo. Levels of significance: *p⩽0.05; **p⩽0.01; ***p⩽0.001. PAC-SYM, patient assessment of constipation symptoms. Symptoms are rated on a 5-point scale: 0 (absent) to 4 (very severe). PRU, prucalopride.